Form Type: 4

SEC EDGAR Link
Accession Number:0001104659-23-008001
Date:2023-01-26
Issuer: Y-MABS THERAPEUTICS, INC. (YMAB)
Original Submission Date:

Reporting Person:

RAJAH VIGNESH
C/O Y-MABS THERAPEUTICS, INC.
230 PARK AVENUE SUITE 3350 NEW YORK, NY 10169

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
EMPLOYEE STOCK OPTION (RIGHT TO BUY) 4.55 2023-01-26 deemed execution date A 32,000 (a) 2033-01-26 common stock 32,000 $4.55 32,000 direct
Footnotes
IDfootnote
f1 stock options granted to the reporting person pursuant to the 2018 equity incentive plan of y-mabs therapeutics, inc.
f2 the stock option shall vest and become exercisable as to 25% of the shares subject to the option on january 26, 2024, and thereafter vests and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the reporting person on each vesting.

Elevate your investments